Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AGA2115 in Healthy Volunteers
NCT06086613Phase 1Completed
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AGA2115 in osteogenesis imperfecta (OI) (4 arms), sponsored by Angitia Biopharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2023; status: completed.
02
Drugs
AGA2115
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT06086613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086613.